Ramosetron

Lung Neoplasms

Yonsei UniversitySmall moleculePhase 2Dormant

CCC

54/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 73/ 100

Competitive context

52 Active assets in the Lung Neoplasms cohort.

Asset / Sponsor	Phase	Rating
Carboplatin Nanfang Hospital, Southern Medical University	Phase 4	BB
Nivolumab Hospital Israelita Albert Einstein	Phase 2	BB
BELAGENPUMATUCEL-L (SK-LU-1) NovaRx Corporation	Phase 3	BB
Icotinib Fuda Cancer Hospital, Guangzhou	Phase 4	BB
Cyclophosphamide Pfizer	Phase 3	BB

View all 50 →

Same molecule, other indications

Ramosetron is also rated in:

breast cancerDormant

BB

Indicative ·

68 / 100

Uterine Myoma, Ovary Neoplasm, AdenomyosisDormant

B

Indicative ·

60 / 100

chemotherapy-induced toxicityDormant

B

Indicative ·

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.